




FIG. 1A




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 3A




FIG. 3B

7/29




**FIG. 4A**




**FIG. 4B**




FIG. 4C

9/29




FIG. 5A






FIG. 5B

10/29



11/29




FIG. 7

12/29




FIG. 8

PRMT5 inhibitor of formula I




FIG. 9A




FIG. 9B




FIG. 10




FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D



FIG. 11E




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 12D




FIG. 12E




FIG. 12F




FIG. 12G

**Cholangiocarcinoma**




**FIG. 13A**

**NSCLC (adeno)  
PDX**






**FIG. 13B**






**FIG. 13E**




FIG. 14A




FIG. 14B




FIG. 15

SW1573




FIG. 16A

LN18




FIG. 16B

RT112/84




FIG. 16C